Quinolinate Accumulation in the Brains of the Quinolinate Phosphoribosyltransferase (QPRT) Knockout Mice by Shin-Ichi Fukuoka et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Quinolinate Accumulation in the Brains of  
the Quinolinate Phosphoribosyltransferase 
(QPRT) Knockout Mice 
Shin-Ichi Fukuoka1, Rei Kawashima1,2,3, Rei Asuma1,  
Katsumi Shibata4 and Tsutomu Fukuwatari4 
1Department of Chemistry and Biological Science,  
College of Science and Engineering, Aoyama Gakuin University,  
Chuo-ku, Sagamahara-shi, Kanagawa, 
2Department of Gastroenterology, Research Institute,  
National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, 
3Department of Biochemistry, Graduate School of Medical Sciences,  
Kitasato University, Minami-ku, Sagamahara-shi, Kanagawa, 
4Department of Life Style Studies, School of Human Cultures,  
The University of Shiga, Hassaka-cho, Hikone-shi, Shiga,  
Japan 
1. Introduction 
The kynurenine pathway (KP) is the main route of L-tryptophan catabolism, thus resulting 
in the production of the essential pyridine nucleotide, nicotinamide adenine dinucleotide 
(NAD+) (Figure 1) (Stone, 1993). Quinolinic acid (QA) is one of the KP metabolites, which 
are synthesized from the essential amino acid tryptophan (Trp). QA is a potent endogenous 
excitotoxin of neuronal cells that acts as N-methyl-D-aspartate (NMDA) receptor agonist. 
Quinolinate phosphoribosyltransferase (QPRT) is the only enzyme that degrades QA in 
mammalian cells, so the concentration of QA is modulated directly by the QPRT activity. 
QA is an endogenous excitotoxin acting on N-methyl-D-aspartate receptors (NMDARs) 
which leads to pathological and neurochemical features similar to those observed in HD. 
Neurons expressing high levels of NMDARs are lost early from the striatum of individuals 
affected with Huntington’s Disease (HD), and injection of NMDA receptor agonists, such as 
QA, into the striatum of rodents or non-human primates mimics the pattern of neuronal 
damage observed in HD. When QA is loaded into rat brains by autodialysis, the striatal 
region is specifically severely damaged (Schwarcz & Köhler, 1983). An autoradioreceptor 
assay showed that the number of NMDA glutamate receptors in patients of HD was 
reduced by 93% (Young et al., 1988), thus supporting the hypothesis that an endogenous 
agonist of the receptor is primarily responsible for the neural degradation associated with 
the disease. Unlike kainate or ibotenate, QA is thought to be the only physiological agonist 
for the NMDARs involved in the disorder (Stone et al., 1981). Thus, a dysfunction of QA 
metabolism in the human brain has been postulated to be involved in the pathogenesis of 
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such neurodegenerative disorders as epilepsy, Alzheimer’s Disease (AD) and HD (the 
“quinolinate hypothesis”) (Schwarcz et al., 1986).  
 
Fig. 1. 
However, this hypothesis has not yet been corroborated by the measurement of endogenous 
QA in neurodegenerative disorders. In this study, we generated QPRT gene deficient mice 
(QPRT knockout mice) to investigate this hypothesis in vivo. We succeeded in detecting the 
endogenous QA accumulation-induced neurodegenerations in the striatum of middle-aged 
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QPRT knockout (KO) mice by an immunohistochemical analysis. In KO mice, the expression 
levels of KP enzymes and NMDA receptor (NMDAR) subunits were altered compared to 
those of wild type (WT) mice. The expression of the NR2B subunit was also significantly 
increased in middle-aged KO mice. The results of biochemical analyses indicated that QA 
tended to exert NMDAR-mediated excitotoxiciy in the brains of these mice. We observed 
behavioral disorders in QPRT KO mice using two behavioral tests. Many previous studies 
have demonstrated that disturbances in gait are symptomatic of Parkinson's Disease (PD) 
and HD. Gait abnormalities in PD include a shortened stride length. HD also shows gait 
abnormalities include changes in stride length (Koller & Trimble, 1985). We therefore 
measured the stride length of KO mice based on these studies. We found that the aged 
QPRT KO mice displayed shortening of their strides compared to the WT group. In contrast, 
the middle-aged QPRT KO mice did not exhibited any significant gait abnormalities. 
Fernagut et al. reported that the stride length is a reliable index of motor disorders due to 
basal ganglia dysfunction in mice (Carter et al., 1999). Our findings suggest that the striatal 
neuronal lesions in the QPRT KO mice progressed with age, such that the younger mice had 
not yet developed sufficient basal ganglia dysfunction to result in a change in gait. The 
shortening of strides may be an event that occurs during the later stage of 
neurodegeneration. 
2. Generation of QPRT gene deficient models 
2.1 Construction of the QPRT gene targeting vector 
Based on the genomic information obtained previously and using genomic clones of the 
129 Svj mouse QPRT gene, a 2.9 kb 50 homologous recombination region including a 
portion of exon 2, intron 3, exon 3, and a portion of intron 4 was amplified by PCR. A 
PGK-βgeo selection marker cassette was ligated and subcloned into the targeting vector 
with the MC1-diphtheria toxin A gene to select against nonhomologous recombination 
(Figure 2a). 
2.2 Generation of the QPRT disrupted mice 
The constructed targeting vector was introduced into a 129 Svj mouse ES cell line (Genome 
Systems) by electroporation. ES cells were selected in media containing G418, and the 
surviving cells were purified by dilution to obtain single clones. Homologous recombination 
in the ES cells was confirmed by a Southern blotting analysis using a probe localized 50 
methods. The positive clone was injected into C57BL/6N mouse blastocysts to obtain 
chimeric mice that transmitted the mutation through the germline. Mice were bred and 
maintained using standard mouse husbandry procedures. The detailed physiological and 
biochemical analyses of the QPRT gene deficient mice will be published elsewhere. 
2.3 Validation studies 
Genomic DNA extracted from mice tails was used for genotyping PCR. Figure 2b is an 
electropherogram of the mouse DNA amplification products. Figure 2b is an 
electropherogram of the mouse DNA amplification products. WT, heterozygous (HZ) and 
KO mice showed distinct band patterns.  
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Fig. 2. Generation of QPRT gene deficient mice. WT, wild type mice; KO, QPRT KO mice. (a) 
The targeting strategy used for QPRT gene disruption. Exons are represented as numbered 
boxes. DT-A, diphtheria toxin-A. (b) An agarose gel showing genotyped PCR amplicons. 
Genomic DNA extracted from mouse tails were used for PCR with primer pairs for the 
QPRT and PGK-βgeo genes. The product sizes are 398 and 221 base pairs (bp), respectively.  
3. Morphological analysis 
3.1 The presence of QA in the brains 
The QA in the brain of middle-aged (18-week-old) WT and QPRT KO mice was stained 
using an anti-QA antibody (Figure 3). The histochemical analyses were performed with 
frozen-section tissues prepared from brains fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS). The frozen sections were excised and embedded in O. C. T. compound 
for cryosectioning, then dried and treated with 5% BSA for 30 min at room temperature. The 
tissues were incubated with 5 µg/ml rabbit anti-QA antibody (Ab) (Sigma, MO) for 12 hours 
at 4°C, followed by 0.5 µg/ml secondary biotinylated donkey anti-rabbit IgG Ab (Molecular 
Probes, OR) for 2 hours at room temperature. The immunostaining was visualized with a 
VECTASTAIN ABC kit (Vector Laboratories, CA) using DAB as the chromagen. The images 
were captured with a fluorescence microscope (Axioplan2; Carl Zeiss Inc., Jena, Germany) 
equipped with a CCD camera. The staining intensities were determined by using the Image-
J software program to measure the stained areas in each striatum of sections after the 
experiment. Stained cells existed in both groups, especially in their striatum. There was no 
consistent pattern of labeling with regard to specific cell types. Quantification of QA 
a 
b 
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staining intensities suggested that there were high QA levels in the middle-aged KO mouse 
striatum. In the striatum, KO mice showed approximately two times the amount of QA 
staining intensity compared to WT mice (Data not shown). 
 
 
Fig. 3. Detection of QA by immunostaining of the striatum of WT and QPRT KO mice. WT, 
wild type mice; KO, QPRT KO mice. The frozen sections of middle-aged WT and KO brains 
were labeled by anti-QA polyclonal antibodies. The QA-positive cells were stained in the 
striatum of WT (a, left) and KO (a, right). 
3.2 Detection of neurodegeneration 
According to the results of the morphological analysis using the QA antibody, we prepared 
sections from middle-aged WT mice and QPRT KO mice to detect neuronal degeneration by 
Fluoro Jade C staining (Figure 4).  
To detect neurodegeneration, the tissues were treated with fluoro-jade C (Histo-Chem Inc.; 
Jefferson, AR) according to the previously described method. The slides bearing frozen cut 
tissue sections were first immersed in a basic alcohol solution consisting of 1% sodium 
hydroxide in 80% ethanol for 5 min. They were then rinsed for 2 min in 70% ethanol, for 2 
min in distilled water, and then incubated in 0.06% potassium permanganate solution for 10 
min. Slides were subsequently transferred for 10 min to a 0.0001% solution of Fluoro-Jade C 
dissolved in 0.1% acetic acid vehicle. The slides were then rinsed through three changes of 
distilled water for 1 min per change. Excess water was drained onto a paper towel, and the 
slides were air dried on a slide warmer at 50°C for at least 5 min. The air dried slides were 
then cleared in xylene for at least 1 min and then coverslipped with entellan new (Merck 
Inc., Japan) non-fluorescent mounting media.  
The neurons in the striatum of the KO mouse brains were labeled in their cell bodies. In 
contrast, there were few stained neurons in the WT mouse brain sections. These results 
indicate that neurodegeneration occurred remarkably in the middle-aged QPRT KO mouse 
striatum, but not in those of WT mice.  
WT KO 
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Fig. 4. Neuronal degeneration in the WT and QPRT KO mouse striatum stained with Fluoro-
Jade C. WT, wild type mice; KO, QPRT knockout mice. 25µm frozen brain sections of 
middle-aged WT (right) and KO (right) mice were used for immunofluoresence studies with 
Fluoro-Jade C staining. The degenerated neurons were labeled in their cell bodies. 
4. Detection of gene expressions 
4.1 The gene expression of kynurenine pathway enzymes in the striatum of WT and 
QPRT KO mice  
We detected the mRNA expression levels of metabolic enzymes in the KP (Figure 1) to 
clarify the role of metabolism in the QPRT KO mice. To determine the mechanism of KP 
metabolism in the middle-aged (14 ~ 22-week-old) and aged (68-week-old) mouse striatum, 
we analyzed the gene expression levels of KP enzymes by real-time PCR using primers for 
IDO, TDO, KATII, KYNase, KMO, 3-HAO and ACMSD. The total RNA was extracted from 
the mouse striatum using TRIZOL (Invitrogen, CA). The purity of RNA was confirmed by 
spectrophotometer readings at 260/280 nm. Total RNA was reverse-transcribed with the 
PrimeScript RT reagent kit (TaKaRa) and amplified by PCR. For KP enzyme genes (Figure 
1), the following primers were used; IDO, 5'-TTCTTCTTAGAGTCAGCTCCCC (sense) and 
TCACAGAGACCAGACCATTCAC-3' (antisense); TDO, 5’-AAGAGGAACAGATGGCAGAG 
(sense) and TCGTCGTTCACCTTTACTCA-3’ (antisense); KAT II, 5’–CGGTTTGAAGA 
CGACTTGA (sense) and TTGGGTGGGTAGTTGACAGT-3’ (antisense); KYNase,  
5’-AGCCCATGAGAAAGAAATAG (sense) and TGCCGCTTTGGAGTAG-3’ (antisense); 
KMO, 5’-CGCGATCATGCCCTCTA (sense) and GGACCCAAGGACAAAGAGTC-3’ 
(antisense); 3-HAO, 5'-TTGAGTGGTTGAGAGCTGTCAC (sense) and GGCTATGGCTG 
TTAGAAGATCG-3' (antisense); ACMSD, 5'-GGTACATGCCTCTTACATCAGC (sense) and 
GCTATCCTAGAGCTTGCTATGC-3' (antisense); QPRT, 5'-GCTCCTGTTACCCCCTACAACC 
(sense) and GGATGCAAAATTGAGGCCCGGG-3' (antisense). GAPDH was used in each 
reaction as an internal standard. For quantitative analysis, the SYBR Premix Ex TaqTM 
(TaKaRa) was used according to the manufacturer’s instructions in a LightCycler® 480 Real-
Time PCR System (Roche, Basel, Schweiz). The conditions for the reaction were as follows: 
5 s at 95°C and 20 s at 60°C for 40 cycles.  
WT KO 
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In the middle-aged mice, the mRNA levels of ACMSD in the striatum of QPRT KO mice 
were lower than those in the WT group (P = 0.036). In contrast, no significant differences in 
the mRNA expression levels were seen in other KP enzymes (Figure 5).  
On the other hand, the aged groups showed the opposite results for ACMSD expression. 
The mRNA levels of ACMSD in the QPRT KO mice were increased significantly compared 
to those of WT mice (P = 0.0088). However, in both the middle-aged and aged groups, there 
were no significant changes in any of the other KP enzymes between the WT and KO mice. 
4.2 The gene expression levels of NMDAR subunits in the striatum of WT and QPRT 
KO mice 
We next investigated the effects of QPRT deletion on the glutamatergic pathway. The 
mRNA expression of NMDAR subunits in the striatum of middle-aged and aged WT and 
QPRT KO mice were analyzed by real-time PCR (Figure 6). In the middle-aged QPRT KO 
group, the NR2B subunit mRNA expression level increased approximately two-fold 
compared to the WT group (P = 0.002). In addition, the NR2A subunit genes in the KO 
mouse striatum showed a tendency toward an increased expression compared to the WT 
group. However, there were no significant differences for any other subunits. 
In the aged KO mouse group, the mRNA expression levels of the NR1, NR2A and NR2B 
subunits were significantly higher than those of the WT group (P = 0.016, 0.049 and 0.044, 
respectively). KO mice also showed two-fold increased expression of the NR2D subunit (P = 
0.015). However, the NR2C subunits did not show any significant differences in expression 
between WT and KO mice.  
These results about NMDAR expression levels suggested that there were similar propensities 
with regard to about the expression of NR2A and NR2B subunits in the middle-aged and aged 
groups, but that more subunits were affected by QPRT deficiency in the aged group. 
5. Discussion 
In this study, we generated QPRT gene deficient mice (QPRT knockout mice) and confirmed 
that the mRNA and protein expression of QPRT were not detected in the tissues of the 
QPRT KO mice. Therefore, it is expected that endogenous QA cannot be degraded by QPRT 
in these mice, allowing for the possible accumulation of QA. According to the “quinolinate 
hypothesis” and other previous studies utilizing animal models of neurodegenerative 
disorders, the accumulation of QA was associated with remarkable abnormal phenotypes 
such as defects in growth and development, such as were observed in a mouse model of 
Huntington’s disease (HD) (Dellen, 2008). However, the QPRT KO mice exhibited normal 
phenotypes. In our long-term follow-up study, the changes in the body weight and intake of 
food were almost the same in the QPRT KO mice as in the wild type (WT) mice (data not 
shown). These results made us wonder why the QPRT KO mice did not show any effects in 
their growth and development. We assumed that there were two possibilities that needed to 
be investigated. First, there was the possibility that the QA concentrations in the brains of 
QPRT KO mice were decreased to nontoxic levels due to changes in the expression levels of 
kynurenine pathway metabolic enzymes. The second possibility was that there might have 
been a change in the mechanism of NMDARs-mediated QA excitotoxicity in the presence of 
excessive QA. Based on these possibilities, we investigated the mechanisms of QA 
accumulation, degradation and excitotoxicity in QPRT KO mice. 
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Fig. 5. The mRNA expression levels of KP enzymes in the striatum tissue samples of WT and 
QPRT KO mice. WT, wild type mice; KO, QPRT knockout mice. Total RNA extracted from 
middle-aged (14~22-week-old) and aged (68-week-old) mouse striatum samples was subjected 
to real time quantitative RT-PCR. The figures show the gene expression levels of KP enzymes 
IDO (middle-aged,WT: n = 4, KO: n = 8, aged, WT: n = 3, KO: n = 6), TDO (middle-aged, WT:  
n = 4, KO: n = 6; aged, WT: n = 3, KO: n = 5), KATII (middle-aged,WT: n = 3, KO: n = 6; aged, 
WT: n = 3, KO: n = 6), KYNase (middle-aged,WT: n = 4, KO: n = 6; aged, WT: n = 3, KO: n = 6), 
KMO (middle-aged,WT: n = 3, KO: n = 4; aged, WT: n = 3, KO: n = 6), 3-HAO (middle-
aged,WT: n = 3, KO: n = 7; aged, WT: n = 3, KO: n = 6), ACMSD (middle-aged,WT: n = 3, KO: 
n = 6; aged, WT: n = 3, KO: n = 6) and QPRT (middle-aged,WT: n = 3, KO: n = 7; aged, WT:  
n = 3, KO: n = 6). The values are shown as the ratios of KP enzymes / GAPDH (internal 
standard). The data are presented as the means ± S.D. *, p < 0.05, **, p < 0.01. (Student’s t-test). 
WT 
KO 
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Fig. 6. The mRNA expression levels of NMDAR subunits in striatum tissue samples from 
WT and QPRT KO mice. WT, wild type mice; KO, QPRT knockout mice. Total RNA was 
extracted from middle-aged (14~22-week-old) and aged (68-week-old) mouse striatum 
samples, and the mRNA expression levels of NMDAR subunits was determined by real time 
quantitative RT-PCR. The figures show the gene expression levels of NMDAR subunits NR1 
(middle-aged,WT: n = 6, KO: n = 7; aged, WT: n = 3, KO: n = 6), NR2A (middle-aged,WT:  
n = 5, KO: n = 7; aged, WT: n = 3, KO: n = 6), NR2B (middle-aged,WT: n = 5, KO: n = 8; aged, 
WT: n = 3, KO: n = 6), NR2C (middle-aged,WT: n = 5, KO: n = 8; aged, WT: n = 3, KO: n = 6), 
and NR2D (middle-aged,WT: n = 5, KO: n = 7; aged, WT: n = 3, KO: n = 6). The values are 
shown as the ratio of NMDAR subunits/GAPDH (internal standard). The data are 
presented as the means ± S.D. *,p < 0.05. (Student’s t-test ).  
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We first tried to visualize the intrastriatal QA in mouse brain sections to clarify whether QA 
accumulated in the brains of the QPRT KO mice. In human and rat brains, QA is present at 
concentrations in the high nanomolar range (Wolfensberger, 1983). An HD study revealed 
that QA levels were increased (by 300-400%) in the neostriatum of human with early stage 
HD compared to controls (Guidetti, 2004)]. By an immunohistochemical analysis using an 
anti-QA polyclonal antibody, we observed that the number of QA-positive cells in the 
striatum of middle-aged QPRT KO mice was higher than in WT mice. This result suggested 
that QA does indeed accumulate in the QPRT KO mice. An in vitro study showed that 
prolonged exposure of rat organotypic cortico-striatal cultures to as little as 100 nM QA 
results in characteristic excitotoxic damage (Whetsell & Schwarcz, 1989). 
Using immunohistochemical detection of QA, we tried to validate the existence of 
neurodegenerarion in the striatum of middle-aged QPRT KO mice. Several previous studies 
demonstrated that selective striatal neuronal damage occurs in the striatum of HD patients. 
Therefore, we and others have postulated that a pathological elevation of QA levels may 
produce excitotoxic neurodegeneration in HD. We used fluoro-jade C staining for detection 
of neuronal degeneration. As a result, there were an increased number of degenerated 
neurons in the striatum of QPRT KO mice compared to WT mice. These results were 
consistent with QA accumulation in the striatum of the QPRT KO mice. We hypothesized 
that the neuronal degeneration in the striatum of KO mice might have been induced by the 
high levels of QA due to the QPRT deficiency. 
We revealed significant differences in the gene expression levels of KP enzymes between 
WT and QPRT KO mice. The expression levels of ACMSD, which degrades the QA 
precursor α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) in the striatum of middle-
aged QPRT KO mice were lower than those of WT mice. In middle-aged QPRT KO mice, 
this change in KP metabolism might promote QA production, because QA is non-
enzymatically derived from ACMS (Figure 1). This is consistent with the results of our 
immunohistochemical staining for QA. However, the results in the aged groups showed the 
opposite, with an increase in expression in the QPRT KO mice compared to the WT mice. 
This may reflect the acquisition of a defense mechanism against accumulation of QA in the 
aged QPRT KO mice, and we expected that this mechanism was established during the 
aging process. A reciprocal relationship between ACMSD mRNA and enzymatic activity 
was described by previous studies; the fluctuation of hepatic ACMSD mRNA expression 
was followed by that of ACMSD activity (Tanabe et al., 2002), and in the mouse brain, the 
changes in ACMSD expression at the message levels are shown to be highly correlated to 
those at the enzyme activity levels. This suggests that the quantification of the message 
levels with the real-time PCR technique is useful to address the regulation of ACMSD 
expression and QA levels (Fukuoka et al., 2002). Although we have not measured the 
enzymatic activities in the different groups of mice, based on the previous studies, we 
speculated that the mRNA expression levels of ACMSD observed in our present study were 
reflective of the enzymatic activity. 
Because QA is known as a selective N-methyl-D-aspartate receptor (NMDAR) agonist, we 
determined the mRNA expression levels of NMDAR subunits to evaluate the mechanism 
underlying the neurotoxicity of endogenous QA.  
The expression of functional recombinant NMDARs in mammalian cells requires the co-
expression of at least one NR1 and one NR2 subtype. The stoichiometry of NMDARs has not 
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yet been established conclusively, but the current consensus is that NMDARs are tetramers 
that most often incorporate two NR1 and two NR2 subunits of the same or different 
subtypes. In the case of middle-aged QPRT KO mice, only the NR2B subunit expression 
levels were significantly increased compared to the levels in WT mice. In contrast, the 
expression levels of both the NR2A and NR2B subunits were increased in the aged QPRT 
KO mice compare to the aged WT mice. Previous studies have elucidated that the 
pharmacological and functional properties of NMDARs depend heavily on the NR2 subunit 
composition. Moreover, other groups have confirmed that the critical factor affecting the 
NMDAR activity is the subunit composition: NR2B-containing NMDARs promote neuronal 
death, while NR2A-containing NMDARs promote neuronal survival. Heng et al. created 
double-mutant mice by crossing a murine genetic model of HD to a transgenic mouse 
overexpressing the NMDAR–NR2B subunits (Tang et al., 1999; Heng et al., 2007) and their 
recent study showed that the double-mutant mice exhibited a significant decrease in striatal 
neuron number and striatal volume. This result demonstrated that the overexpression of the 
NR2B subunit leads to the degeneration of striatal neurons. Based on these previous studies 
and our present findings, we believe that the high sensitivity of striatal neurons in the 
middle-aged mice to damage was due to their high expression of the NR2B subunit. 
Similarly, we believe that the aged QPRT KO mice expressed high levels of the NR2A 
subunit as an adaptive neuroprotective mechanisms.  
6. Conclusion 
In summary, our study detected the presence of endogenous QA accumulation and QA-
induced neurodegeneration in the striatum of middle-aged QPRT KO mice. Our results 
raised the possibility that QPRT KO mice are able to be used as a model of endogenous QA 
accumulation mimicking various human neurodegenerative conditions. Although it was 
difficult to demonstrate the “quinolinate hypothesis” in previous in vivo studies, the new 
QPRT KO mouse model will therefore be a useful model for further investigating this 
hypothesis.  
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movements, loss of intellectual capabilities and behavioural disturbances. Since the identification of the
causative mutation, there have been many significant developments in understanding the cellular and
molecular perturbations. This book, "Huntington's Disease - Core Concepts and Current Advances", was
prepared to serve as a source of up-to-date information on a wide range of issues involved in Huntington's
Disease. It will help the clinicians, health care providers, researchers, graduate students and life science
readers to increase their understanding of the clinical correlates, genetic aspects, neuropathological findings,
cellular and molecular events and potential therapeutic interventions involved in HD. The book not only serves
reviewed fundamental information on the disease but also presents original research in several disciplines,
which collectively provide comprehensive description of the key issues in the area.
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